New hope for nail psoriasis: drug shows promise in phase 3 trial
NCT ID NCT03897075
First seen Apr 12, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study tested a drug called tildrakizumab in 99 adults with moderate to severe nail psoriasis, a condition causing nail damage and pain. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and symptoms. The goal was to find a safe, effective treatment for this hard-to-treat form of psoriasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Dermatology & CRI (Site 18)
Encinitas, California, 92007, United States
-
Center for Clinical Studies (Site 11)
Houston, Texas, 77004, United States
-
Center for Clinical Studies Cypress (Site 17)
Cypress, Texas, 77433, United States
-
Clinical Partners, LLC (Site 08)
Johnston, Rhode Island, 02919, United States
-
Clinical Science Institute (Site 14)
Santa Monica, California, 90404, United States
-
Dermatology Research Associates (Site 09)
Los Angeles, California, 90045, United States
-
First OC Dermatology (Site 07)
Fountain Valley, California, 92708, United States
-
Florida Academic Centers Research and Education, LLC (Site 21)
Coral Gables, Florida, 33134, United States
-
Forest Hills Dermatology Group (Site 04)
Forest Hills, New York, 11375, United States
-
Fremantle Dermatology (Site 40)
Fremantle, WAUS, 6160, Australia
-
North Eastern Health Specialists (Site 46)
Campbelltown, South Australia, 5073, Australia
-
Premier Dermatology (Site 47)
Kogarah, New South Wales, 2217, Australia
-
Progressive Clinical Research (Site 27)
San Antonio, Texas, 78213, United States
-
Renstar Medical Research (Site 23)
Ocala, Florida, 34470, United States
-
Skin Health Institute Inc. (Site 43)
Carlton, Victoria, 3053, Australia
-
St George Dermatology & Skin Cancer Centre (Site 45)
Kogarah, New South Wales, 2217, Australia
-
Veracity Clinical Research/ Specialist Connect(Site 44)
Woolloongabba, QSLD, 4102, Australia
Conditions
Explore the condition pages connected to this study.